1256388-51-8 | Ledipasvir

Packsize	Purity	Availability	Price	Discounted Price
5mg	95%	in stock	$25.00	$18.00
25mg	95%	in stock	$50.00	$35.00
100mg	95%	in stock	$75.00	$52.00
250mg	95%	in stock	$140.00	$98.00
1g	95%	in stock	$319.00	$223.00

Description

• Catalog Number: AI16749
• Chemical Name: Ledipasvir
• CAS Number: 1256388-51-8
• Molecular Formula: C49H54F2N8O6
• Molecular Weight: 888.9999
• MDL Number: MFCD25976756
• SMILES: COC(=O)N[C@H](C(=O)N1CC2(C[C@H]1c1ncc([nH]1)c1ccc3-c4c(C(c3c1)(F)F)cc(cc4)c1ccc3c(c1)[nH]c(n3)[C@@H]1[C@H]3CC[C@@H](N1C(=O)[C@H](C(C)C)NC(=O)OC)C3)CC2)C(C)C

Computed Properties

• Complexity: 1820
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 6
• Heavy Atom Count: 65
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 12
• XLogP3: 7.4

Literature

• Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.

  Drugs 20170701

• Interferon-free therapy for hepatitis C: The hurdles amid a golden era.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20150901

• Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

  The New England journal of medicine 20150820

• Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.

  Hepatology (Baltimore, Md.) 20150601

• Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1.

  Expert opinion on pharmacotherapy 20150401

• Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C.

  Drugs 20150401

• Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.

  JAMA 20150301

• Ledipasvir and sofosbuvir: Interferon free therapy for hepatitis C virus genotype 1 infection.

  World journal of virology 20150212

• An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.

  Canadian journal of gastroenterology & hepatology 20150101

• Changing the face of hepatitis C management - the design and development of sofosbuvir.

  Drug design, development and therapy 20150101

• Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection.

  Expert opinion on investigational drugs 20140401

• Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection.

  Journal of medicinal chemistry 20140313

• Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.

  Antimicrobial agents and chemotherapy 20140201

• Side effects of alpha interferon in chronic hepatitis C.

  Hepatology (Baltimore, Md.) 19970901